ARTICLE | Company News
Heptares, Shire deal
May 16, 2011 7:00 AM UTC
Heptares granted Shire an option to license exclusive, worldwide rights to a preclinical adenosine A2A receptor (ADORA2A) antagonist. Heptares said inhibition of the receptor has been proved to be ef...